Evid Invest
Holders — by stockHoldings — by fund

Aisling Capital Management LP

Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001766721

$471.6M

disclosed book value

14

positions

72.5%

largest position share

Positions, as of 2026-06-30

top 14 of 14 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held

#IssuerSharesValue% of book
1BBIOBRIDGEBIO PHARMA INC4.6M$341.8M72.5%
2GLUEMONTE ROSA THERAPEUTICS INC1.6M$37.6M8%
3SNDXSYNDAX PHARMACEUTICALS INC1.3M$28.8M6.1%
4CMPSCOMPASS PATHWAYS PLC1.4M$20.3M4.3%
5BCAXBICARA THERAPEUTICS INC568,919$16.9M3.6%
6BBOTBRIDGEBIO ONCOLOGY THERAPEUT1.0M$7.8M1.6%
7SRRKSCHOLAR ROCK HLDG CORP77,031$4.2M0.9%
8UROGEN PHARMA LTD108,000$4.0M0.8%
9BMEABIOMEA FUSION INC2.0M$3.0M0.6%
10ACRSACLARIS THERAPEUTICS INC434,455$2.3M0.5%
11EPRXEUPRAXIA PHARMACEUTICALS INC325,000$2.1M0.5%
12VTVTVTV THERAPEUTICS INC50,000$1.9M0.4%
13MRKRMARKER THERAPEUTICS INC325,370$478,2930.1%
14OKURONKURE THERAPEUTICS INC88,607$404,0480.1%

Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.

EvidInvest is an independent research and information tool. Figures are calculated from public SEC filings and third-party market data and are provided for informational and educational purposes only. EvidInvest does not provide investment advice, brokerage, or financial services, and is not affiliated with any company it covers. Verify all figures against primary sources before making any decision.